Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Merck Stretches Lead As EU Approves Keytruda In First-Line NSCLC

Executive Summary

Merck & Co just keeps clearing the hurdles to checkpoint inhibitor market domination, with EU approval in the key first-line NSCLC indication coming swiftly after the company snuck in an earlier than expected filing in the US for its chemo combination use.


Related Content

Under Fire, Bristol Plans To Pick Up The IO Pieces
Bristol Falls Further Behind Merck In NSCLC By Pulling Early Combo Filing
AstraZeneca Updates MYSTIC Plan In Bid To Challenge Merck In NSCLC
Game Changer: Merck's Stealth Keytruda-Chemo Filing Stirs NSCLC Market Dynamics


Related Companies